This is a working overview of thymic extract, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-14 and is reviewed periodically as new material appears.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
==== Syrian Arab Republics ==== In 2013, Damascus University instituted a Master's program in Medical Physics, which has significantly contributed to the training of numerous medical physicists across various university and local hospitals, as well as several universities within the Syrian Arab Republic. This program has facilitated the dissemination of knowledge through the publication of several external research articles addressing the role of medical physicists in oncology. Furthermore, it has resulted in the production of multiple academic textbooks in the field of medical physics.
The beginning of the millennium saw the introduction of several independent developments in DEL technology. These technologies can be classified under two general categories: non-evolution-based and evolution-based DEL technologies capable of molecular evolution. The first category benefits from the ability to use off the shelf reagents and therefore enables rather straightforward library generation. Hits can be identified by DNA sequencing, however DNA translation and therefore molecular evolution is not feasible by these methods. The split and pool approaches developed by researchers at Praecis Pharmaceuticals (now owned by GlaxoSmithKline), Nuevolution (Copenhagen, Denmark) and encoded self- assembled chemical (ESAC) technology developed in the laboratory of Prof D. Neri (Institute of Pharmaceutical Science, Zurich, Switzerland) fall under this category. ESAC technology sets itself apart being a combinatorial self-assembling approach which resembles fragment based hit discovery (Fig 1b). Here DNA annealing enables discrete building block combinations to be sampled, but no chemical reaction takes place between them. Examples of evolution-based DEL technologies are DNA-routing developed by Prof. D.R. Halpin and Prof. P.B. Harbury (Stanford University, Stanford, CA), DNA-templated synthesis developed by Prof. D. Liu (Harvard University, Cambridge, MA) and commercialized by Ensemble Therapeutics (Cambridge, MA) and YoctoReactor technology. developed and commercialized by Vipergen (Copenhagen, Denmark). These technologies are described in further detail below.
The bloom strength of a gelatine mixture is the measure of how strong it is. It is defined by the force in grams required to press a 12.5 mm (0.49 in) diameter plunger 4 mm (0.16 in) into 112 g (4.0 oz) of a standard 6.67% w/v gelatine gel at 10 °C (50 °F). The bloom strength of a gel is useful to know when determining the possibility of substituting a gelatine of one bloom strength for a gelatine of another. One can use the following equation:
Sources: en.wikipedia.org
Macrophages and inflammatory components (within 1–2 days) Epithelial-mesenchymal interaction: re-epithelialization (phenotype change within hours, migration begins on day 1 or 2) Fibroblasts and myofibroblasts: progressive alignment, collagen production, and matrix contraction (between day 4 and day 14) Endothelial cells and angiogenesis (begins on day 4) Dermal matrix: elements of fabrication (begins on day 4, lasting 2 weeks) and alteration/remodeling (begins after week 2, lasting weeks to months—depending on wound size).
Scar revision is a process of cutting the scar tissue out. After the excision, the new wound is usually closed up to heal by primary intention, instead of secondary intention. Deeper cuts need a multilayered closure to heal optimally, otherwise depressed or dented scars can result. Surgical excision of hypertrophic or keloid scars is often associated to other methods, such as pressotherapy or silicone gel sheeting. Lone excision of keloid scars, however, shows a recurrence rate close to 45%. A clinical study is currently ongoing to assess the benefits of a treatment combining surgery and laser-assisted healing in hypertrophic or keloid scars. Subcision is a process used to treat deep rolling scars left behind by acne or other skin diseases. It is also used to lessen the appearance of severe glabella lines, though its effectiveness in this application is debatable. Essentially the process involves separating the skin tissue in the affected area from the deeper scar tissue. This allows the blood to pool under the affected area, eventually causing the deep rolling scar to level off with the rest of the skin area. Once the skin has leveled, treatments such as laser resurfacing, microdermabrasion or chemical peels can be used to smooth out the scarred tissue.
== Medical uses == Lemborexant is used in the treatment of insomnia in adults. A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found that lemborexant had an effect size (standardized mean difference (SMD)) against placebo for treatment of insomnia at 4 weeks of 0.36 (95% CITooltip confidence interval 0.08 to 0.63) and at 3 months of 0.41 (95% CI 0.04 to 0.78). Lemborexant had similar effect sizes at 4 weeks as the other evaluated and marketed orexin receptor antagonists suvorexant (SMD 0.31, 95% CI 0.01 to 0.62) and daridorexant (SMD 0.23, 95% CI –0.01 to 0.48), whereas benzodiazepines and Z-drugs generally showed larger effect sizes (e.g., SMDs of 0.45 to 0.83) than lemborexant and the other orexin receptor antagonists. However, the review concluded that lemborexant and eszopiclone among all of the insomnia medications assessed had the best profiles overall in terms of efficacy, tolerability, and acceptability. Compared to benzodiazepines, there is a low risk of developing tolerance and dependence. Memory and attention are not affected the next morning when taking lemborexant.
== Society and culture == In June 2009, the US Food and Drug Administration (FDA) issued a public health advisory for insulin determir after learning that 129,000 stolen vials reappeared and were being sold in the U.S. market. The FDA warned that the stolen vials "may not have been stored and handled properly and may be dangerous for patients to use." The stolen vials were identified as lots XZF0036, XZF0037, and XZF0038.
Sources: en.wikipedia.org
CRC Press, 2001 Tracy, Douglas S.; Nash, Robert A., "A Validation Approach for Laboratory Information Management Systems", Journal of Validation Technology, 2002, 9(1), 6-14 Perry, Douglas, "Laboratory Informatics: Origin, Scope, and its Place in Higher Education", Journal of the Association for Laboratory Automation, 2004, 9(6), 421 - 428 Sterling, James D., "Laboratory Automation Education", Journal of the Association for Laboratory Automation, 2004, 9(5), A11-A12 Sterling, James D., "Laboratory automation curriculum at Keck Graduate Institute", Journal of the Association for Laboratory Automation, 2004, 9(5), 331-335 Taylor, Keith, "The status of electronic laboratory notebooks for chemistry and biology", Current Opinion in Drug Discovery & Development, 2006, 9(3): 348-353 Wood, Simon, "Comprehensive Laboratory Informatics: A Multilayer Approach", American Laboratory, 2007, 39(16), 20-23 Metrick, Gloria, "Three Issues of LIMS/Laboratory Informatics That Can Cost Money", American Laboratory, 2007, 39(21), 10-11 Calva, Diana; Lehman, Mario, "An analysis of the possible applications of Artificial Intelligence Techniques to a Clinical Laboratory Information Management System", International Journal of Computer Science and Network Security, 2008, 8(12), 82-86 Shah, Kim, "Elevating laboratory informatics to assist decision-making", Pharmaceutical Technology Europe, 2009, 21(5)
=== Sequence similarity === EC categories do not reflect sequence similarity. For instance, two ligases of the same EC number that catalyze exactly the same reaction can have completely different sequences. Independent of their function, enzymes, like any other proteins, have been classified by their sequence similarity into numerous families. These families have been documented in dozens of different protein and protein family databases such as Pfam.
== Overdose == In high doses, overdoses, or in some persons not tolerant to opioids, oxycodone can cause shallow breathing, slowed heart rate, cold/clammy skin, pauses in breathing, low blood pressure, constricted pupils, circulatory collapse, respiratory arrest, and death. In 2011, it was the leading cause of drug-related deaths in the U.S. However, from 2012 onwards, heroin and fentanyl have become more common causes of drug-related deaths.
6 May – Terence Etherton, Baron Etherton, 73, British judge and politician, Master of the Rolls (2016–2021), chancellor of the High Court (2013–2016), and member of the House of Lords (since 2021). 20 May – Patrick O'Flynn, 59, British journalist (Daily Express) and politician, MEP (2014–2019), cancer. (death announced on this date) 13 June – Seán Neeson, 79, Northern Irish politician, MLA (1982–1986, 1998–2011). 1 July – David Lipsey, Baron Lipsey, 77, British journalist and life peer (since 1999). 7 July – Norman Tebbit, Baron Tebbit, 94, British politician, secretary of state for employment (1981–1983), chancellor of the Duchy of Lancaster (1985–1987), and MP (1970–1992). 9 July – Ian Blair, Baron Blair of Boughton, 72, British police officer and life peer, Commissioner of Police of the Metropolis (2005–2008), member of the House of Lords (since 2010). 13 July – Mark Schreiber, Baron Marlesford, 93, British politician, member of the House of Lords (since 1991). 17 July – Tommy Gallagher, 82, Northern Irish politician, MLA (1998–2011). (death announced on this date) 18 July – David Alliance, Baron Alliance, 93, Iranian-born British businessman, member of the House of Lords (2004–2025). 22 July – Sir Jamie McGrigor, 6th Baronet, 75, Scottish politician, MSP (1999–2016). (death announced on this date) 29 July – Meghnad Desai, Baron Desai, 85, Indian-born British economist and politician, member of the House of Lords (since 1991). 3 August – Stella Rimington, 90, British author and Director General of MI5 (1992–1996).
The word theory in "the theory of evolution" does not imply scientific doubt regarding its validity; the concepts of theory and hypothesis have specific meanings in a scientific context. While theory in colloquial usage may denote a hunch or conjecture, a scientific theory is a set of principles that explains an observable phenomenon in natural terms. Scientific facts and theories are not mutually exclusive, and evolution is a theory in the same sense as germ theory or the theory of gravitation. The theory of evolution does not attempt to explain the origin of life or the origin and development of the universe. The theory of evolution deals primarily with changes in successive generations over time after life has already originated. The scientific model concerned with the origin of the first organisms from organic or inorganic molecules is known as abiogenesis, and the prevailing theory for explaining the early development of the universe is the Big Bang model. Evolution is not a progression from inferior to superior organisms, and it also does not necessarily result in an increase in complexity. Evolution through natural selection only causes successive generations of a population of organisms to become more fit for their environment than previous generations. A population can evolve to become simpler or to have a smaller genome, and atavistic ancestral genetic traits can reappear after having been lost through evolutionary change in previous generations.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。